Emergent BioSolutions Inc.

Form 3

November 14, 2006

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

**SECURITIES** 

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person

2. Date of Event Requiring Statement

3. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [EBS]

Harsanyi Zsolt

(Last)

(Middle)

(Month/Day/Year) 11/14/2006

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

300 PROFESSIONAL DRIVE

(Street)

(First)

(Check all applicable)

6. Individual or Joint/Group

Filing(Check Applicable Line) 10% Owner \_X\_ Form filed by One Reporting

Officer Other (give title below) (specify below)

Person Form filed by More than One

Reporting Person

GAITHERSBURG, MDÂ 20879

(State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

\_X\_ Director

1. Title of Security (Instr. 4)

(City)

2. Amount of Securities Beneficially Owned (Instr. 4)

4. Nature of Indirect Beneficial Ownership Ownership Form: (Instr. 5)

Direct (D) or Indirect (I) (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** 

(Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4. Conversion or Exercise

Price of

Security

Derivative

5. Ownership Form of Derivative Security:

6. Nature of Indirect Beneficial Ownership (Instr. 5)

Expiration Date

Amount or Title Number of Shares

Direct (D) or Indirect (I) (Instr. 5)

Exercisable Date

### Edgar Filing: Emergent BioSolutions Inc. - Form 3

Director Stock Option (right to buy)  $\hat{A} \stackrel{(1)}{=} 12/01/2014 \begin{array}{c} \text{Class B} \\ \text{Common} \\ \text{Stock} \end{array}$ 

# **Reporting Owners**

Reporting Owner Name / Address

Director 10% Owner Officer Other

Harsanyi Zsolt

300 PROFESSIONAL DRIVE Â X Â Â

GAITHERSBURG, MDÂ 20879

## **Signatures**

/s/Daniel Abdun-Nabi, attorney in fact 11/14/2006

\*\*Signature of Reporting Person Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option is vested with respect to 28,770 shares of Class B Common Stock covered thereby and will vest with respect to the remaining 14,386 shares on June 1, 2007.

Â

#### Remarks:

Exhibit List:

## Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2